 |
|
|
|
|
|
|
|  | May 1, 2008
Abbott, Takeda Conclude TAP Joint Venture | |
|
| | Apr 29, 2008
Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA® for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women | |
|
| | Mar 31, 2008
New Data Showed ACTOS® (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients with Type 2 Diabetes | |
|
| | Mar 19, 2008
Takeda Announces New U.S. Leadership | |
|
| | Mar 19, 2008
Takeda, Abbott Announce Plans to Conclude TAP Joint Venture | |
|
| | Jan 4, 2008
Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | |
|
| | Nov 6, 2007
“Move to AMITIZA” Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down | |
|
| | Oct 24, 2007
Student Scientists Receive Scholarships to Advance Research | |
|
| | Sep 11, 2007
Takeda Statement on ACTOS® (pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association | |
|
| | Jul 30, 2007
Takeda Responds to the FDA Advisory Committee Recommendation | |
|
| | Jul 12, 2007
Sucampo Pharmaceuticals Submits Supplemental New Drug Application for Lubiprostone to Treat Irritable Bowel Syndrome with Constipation | |
|
| | Jun 19, 2007
U.S. Green Building Council Awards Takeda U.S. Home Office LEED Gold Environmental Certification | |
|
| | Jun 6, 2007
Takeda Revises ACTOS® (pioglitazone HCl) Prescribing Label | |
|
| | May 22, 2007
New Study Suggests No Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon | |
|
| | May 21, 2007
New Study Demonstrates that Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation (IBS-C) | |
|
| | May 14, 2007
Takeda Expands Support of Community Health and Wellness Initiatives in Partnership with Two Local Not-for-Profit Organizations | |
|
| | Feb 26, 2007
Takeda and TAP to Promote Sucampo's AMITIZA in the United States | |
|
| | Jan 19, 2007
Takeda Global Research & Development Center, Inc. Names Dr. Mehmood Khan President | |
|
| | Jan 8, 2007
Takeda Pharmaceuticals North America Names Vice President of Human Resources and Administration | |
|
| | Nov 13, 2006
New Data Show ACTOS® (pioglitazone HCl) Halted Progression of Atherosclerosis as Indicated by CIMT in Patients With Type 2 Diabetes | |
|
| | Nov 7, 2006
duetact™ (pioglitazone HCl and glimepiride) Now Available in U.S. Pharmacies | |
|
| | Oct 20, 2006
Takeda Celebrates U.S. Growth with Grand Opening of New Home Office | |
|
| | Oct 16, 2006
Takeda to Sponsor The LaSalle Bank Chicago Marathon | |
|
| | Sep 3, 2006
New Analyses Show ACTOS® (pioglitazone HCl) Reduced Risk of Secondary Stroke by Almost 50 Percent in High-Risk Type 2 Diabetes Patients | |
|
| | Jul 31, 2006
FDA Approves Duetact TM (pioglitazone HCl and glimepiride) for the Treatment of Type 2 Diabetes | |
|
| | Jun 12, 2006
New Results from the Landmark PROactive Trial Found That ACTOS® (pioglitazone HCl) Reduced the Occurrence of Major Adverse Cardiovascular Events | |
|
| | Jun 12, 2006
Cephalon and Takeda Announce Agreement to Co-Promote PROVIGIL® in the United States | |
|
| | Jun 9, 2006
ACTOS® (pioglitazone HCl) To Be Studied In New Trial Investigating Its Effects On Atherosclerosis In Patients With Type 2 Diabetes | |
|
| | May 22, 2006
New Study Finds that Ramelteon Shows Potential for Circadian Phase Shifting | |
|
| | May 22, 2006
New Study Demonstrates that AMITIZA TM(lubiprostone) May Help Improve Symptoms of Irritable Bowel Syndrome with Constipation | |
|
| | May 22, 2006
AMITIZA TM(lubiprostone) Shown Effective and Well-Tolerated | |
|
| | Apr 25, 2006
AMITIZATM(lubiprostone), the First Selective Chloride Channel Activator for the Treatment of Chronic Idiopathic Constipation, Launches in the United States | |
|
| | Apr 3, 2006
Takeda Submits New Drug Application for Extended-Release Type 2 Diabetes Medication, ACTOplus met TM(pioglitazone HCl and metformin HCl) | |
|
| | Feb 22, 2006
Takeda Wins Patent Infringement Litigation against ANDA Filers for Generic ACTOS® | |
|
| | Jan 31, 2006
Sucampo Obtains FDA Approval for AMITIZATM (lubiprostone) Capsules as Treatment for Chronic Idiopathic Constipation in Adults | |
|
| | Nov 22, 2005
Takeda Pharmaceuticals North America Names Chief Compliance Officer | |
|
| | Nov 16, 2005
New Data Shows Takeda's ACTOS® (pioglitazone HCl) Reduced Heart Attacks by 28 Percent in People with Type 2 Diabetes | |
|
| | Oct 26, 2005
Talented Local Students Receive Scholarships for Scientific Advancement Takeda Sponsors 2005-06 ARCS Scholarship Recipients | |
|
| | Sep 20, 2005
PROactive Study Shows Takeda's ACTOS® (pioglitazone HCl) Reduced Heart Attacks, Strokes and Deaths in Patients With Type 2 Diabetes | |
|
| | Aug 29, 2005
ACTOplus metTM (pioglitazone HCl and metformin HCl) Approved by the FDA for Type 2 Diabetes | |
|
| | Jul 22, 2005
FDA Approved ROZEREM TM(ramelteon), First and Only Non-Scheduled Prescription Sleep Medication | |
|
| | Jun 11, 2005
Diabetes Drug ACTOS® (pioglitazone HCl) Showed Anti-Inflammatory Effects | |
|
| | May 17, 2005
Older Adults with Insomnia Report Falling Asleep Faster with Ramelteon | |
|
| | May 17, 2005
Phase III Clinical Program Evaluates Lubiprostone for the Treatment of Constipation-Predominant Irritable Bowel Syndrome | |
|
| | Oct 29, 2004
Takeda Submits New Drug Application for Combination Type 2 Diabetes Medication, Actoplus MetTM (pioglitazone HCl and metformin HCl) | |
|
| | Oct 7, 2004
Takeda Announces Partnership with BioNumerik to Market Tavocept TM, Phase 3 Chemoprotective Agent, in North America | |
|
| | Sep 24, 2004
Takeda Submits New Drug Application for Ramelteon, an Investigational Sleep Drug | |
|
| | Jun 28, 2004
Landmark PROactive Trial Investigates Effect of ACTOS® (pioglitazone HCl) on Cardiovascular Disease Progression | |
|
| | Jun 5, 2004
ACTOS® (pioglitazone HCl) Shows Sustained Efficacy Throughout Two-Year Period in Patients with Type 2 Diabetes | |
|
| | Jun 5, 2004
Studies Show ACTOS ® (pioglitazone HCl) Has Positive Effects on Various Components of Dyslipidemia | |
|
| | Apr 30, 2004
Combination Therapy with ACTOS® (pioglitazone HCl) Shown to Improve Components of Diabetic Dyslipidemia | |
|
| | Jan 6, 2004
Takeda Establishes Global Research and Development Center | |
|
| | Nov 4, 2003
Kos Pharmaceuticals and Takeda Pharmaceuticals North America Announce Multi-Year Co-Promotion Agreement for Niaspan and Advicor | |
|
| | Oct 21, 2003
Takeda Files Patent Infringement Litigation Against ANDA Submissionsfor Generic Pioglitazone | |
|
| | Oct 20, 2003
Takeda Pharmaceuticals North America Shares Early Stage Data on ramelteon, formerly known as TAK-375 | |
|
| | Oct 17, 2003
Employers Seek New Ways to Offer Workers Prescription Drug Benefits | |
|
| | Jun 14, 2003
New Studies Demonstrate Long-Term Efficacy of ACTOS®, Stability of TZD Therapy | |
|
| | Jun 13, 2003
Takeda Pharmaceuticals North America Provides Grant to Support Diabetes Research | |
|
| | May 21, 2003
Takeda Pharmaceuticals North America Shares Early Stage Data on Sleep Compound, TAK-375 | |
|
| | Apr 1, 2003
Takeda Pharmaceuticals North America Initiates Cardiac Clinical Trials | |
|
| | Mar 13, 2003
TPNA Expands Sales Organization To Include Medical Center Sales Force | |
|
| | Jan 21, 2003
Dr. Mehmood Khan Joins TPNA as Vice President, Medical and Scientific Affairs | |
|
